Cost-effectiveness of migraine prevention: The case of topiramate in the UK

Cephalalgia

Volumn 26, Issue 12, 2006, Pages 1473-1482

  Brown, J S ^a   Papadopoulos, G ^b   Neumann, P J ^c   Price, M ^d   Friedman, M ^e   Menzin, J ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d Janssen Cilag Ltd   (United Kingdom)

^e Boston Health Economics Inc   (United States)

Author keywords

Cost effectiveness; Economic; Migraine; Prevention; Topiramate

Indexed keywords

TOPIRAMATE; TRIPTAN DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH SERVICE; HOSPITALIZATION; HUMAN; MEDICAL PRACTICE; MIGRAINE; MORBIDITY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM;

ADULT; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FRUCTOSE; GREAT BRITAIN; HUMANS; MIGRAINE DISORDERS; MODELS, ECONOMIC; NEUROPROTECTIVE AGENTS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 33751168678     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2006.01240.x     Document Type: Article

References (40)

1. Headache Classification Subcommittee of the International Headache. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24 (Suppl. 1):9-160.
2. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2003; 23:519-27.
3. Lipton RB, Stewart WF, Von Korff M. The burden of migraine. A review of cost to society. Pharmacoeconomics 1994; 6:215-21.
4. Lipton RB, Scher AI, Steiner TJ, Bigal ME, Kolodner K, Liberman JN et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003; 60:441-8.
5. Clarke CE, MacMillan L, Sondhi S, Wells NE. Economic and social impact of migraine. QJM 1996; 89:77-84.
6. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tensiontype headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20:131-7.
7. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998; 38:87-96.
8. Harpole LH, Samsa GP, Matchar DB, Silberstein SD, Blumenfeld A, Jurgelski AE. Burden of illness and satisfaction with care among patients with headache seen in a primary care setting. Headache 2005; 45:1048-55.
9. Coukell AJ, Lamb HM. Sumatriptan. A pharmacoeconomic review of its use in migraine. Pharmacoeconomics 1997; 11:473-90.
10. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159:813-8.
11. Solomon GD, Price KL. Burden of migraine. A review of its socioeconomic impact. Pharmacoeconomics 1997; 11 (Suppl. 1):1-10.
12. Holmes WF, MacGregor EA, Dodick D. Migraine-related disability: impact and implications for sufferers' lives and clinical issues. Neurology 2001; 56 (6 Suppl. 1):13-9.
13. Berg J, Stovner LJ. Cost of migraine and other headaches in Europe. Eur J Neurol 2005; 12 (Suppl. 1):59-62.
14. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137:840-9.
15. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Available at http://www.aan.com/professionalspractice/pdfs/g10090.pdf (accessed 2005).
16. Silberstein SD, U.S. Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). St. Paul, MN: American Academy of Neurology 2000.
17. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291:965-73.
18. Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ et al. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251:943-50.
19. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61:490-5.
20. Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005; 45:1012-22.
21. Farkkila M, Bussone G, D'Amico D, Jacobs D, Neto W, Pfeil J. The efficacy of topiramate in migraine prevention: analyses of pooled data from three 26-week, placebo-controlled, double-blind topiramate trials. Presented at the Migraine Trust International Symposium, London, UK, 2004.
22. Adelman JU, Lainez MJA, Jacobs D, Neto W, Shi Y. Safety assessment of topiramate in migraine prevention: pooled results from over 1500 patients. Presented at the 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, 2004.
23. Rapoport AM, Mauskop A, Schwalen S, Wu SC, Pfeil J. Long-term effectiveness of topiramate for migraine prevention: analyses of open-label, extension phase data from two pivotal studies. Neurology 2005; 64 (6 Suppl. 1):A336-A337.
24. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21:271-92.
25. Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics 2002; 20:91-100.
26. Caro G, Getsios D, Caro JJ, Raggio G, Burrows M, Black L. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis. Cephalalgia 2001; 21:12-9.
27. Caro JJ, Caro G, Getsios D, Raggio G, Burrows M, Black L. The migraine ACE model: evaluating the impact on time lost and medical resource use. Headache 2000; 40:282-91.
28. Caro JJ, Getsios D, Raggio G, Caro G, Black L. Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. Headache 2001; 41:456-64.
29. UK National Statistics. UK national statistics. 2005. Available at http://www.statistics.gov.uk/statbase/ tsdtimezone.asp Last accessed January 2006.
30. Department of Trade and Industry. DTI employment relations - UK public and bank holidays. 2005. Available at http://www.dti.gov.uk/er/bankhol.htm Last accessed January 2006.
31. UK National Statistics. Annual survey of hours and earnings (ASHE) - 2005 results. Table 8, Place of Residence by Local Authority. 2005. Available at http://www. statistics.gov.uk/StatBase/Product.asp?vlnk=14203 Last accessed January 2006.
32. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13:437-52.
33. Von Korff M, Stewart WF, Simon DJ, Lipton RB. Migraine and reduced work performance: a population-based diary study. Neurology 1998; 50:1741-5.
34. Osterhaus JT, Townsend RJ, Gandek B, Ware JE. Measuring the functional status and well-being of patients with migraine headache. Headache 1994; 34:337-43.
35. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology 2000; 55 (9 Suppl. 2):29-35.
36. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998; 51:1115-28.
37. Brown JS, Neumann P, Papadopoulos G, Ruoff G, Maizels M, Diamond M, Menzin J. Impact of migraine frequency on health utilities. Value Health 2005; 8:318.
38. Brown JS, Ruoff G, Neumann P, Papadopoulos G, Maizels M, Diamond M, Menzin J. Patient health perceptions and the burden of migraine: a multi-site study. Neurology 2005; 64 (6 Suppl. 1):A309.
39. Diamond M, Dahlof C, Papadopoulos G, Neto W. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005; 45:1023-30.
40. Cost-effectiveness in health and medicine. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press 1996.